Search

About us

The European Hematology Association (EHA): “Towards prevention, cure, and quality of life for all patients with blood disorders”.

Read more

Policy & advocacy

Our mandateEHA’s policy and advocacy work is guided by the European Affairs Committee, which sets the priorities, formulates positions and actively contributes to engagement with policy makers and stakeholders.

Read more

Privacy statement

May 21, 2021

Privacy Statement European Hematology Association

Personal Data is processed in the context of the services provided by European Hematology Association (hereinafter also; “EHA”).

Read more

Hospital pharmacists and regulators lead the way on shortages

EHA welcomes initiatives but calls for more focus on causes

Medicine shortages have a negative impact on the quality and cost of treatments and on patient access to the best possible care.

Read more

EHA Award winners put in the spotlight in Copenhagen

The EHA-José Carreras Non-Clinical Junior Fellowship is made possible with the support of the German José Carreras Foundation.

Read more

Does the patient with myelofibrosis feel better through Pacritinib?

Pacritinib is an oral next-generation multikinase inhibitor with specificity for JAK2 and FLT3 being evaluated to treat myelofibrosis in two Phase 3 trials.

Read more